SCHEMBL4147576

SCHEMBL4147576

CC/C=C(\C(C)=O)C(=O)OCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.69
NPSR1 Q6W5P4 3/20 0.52
ALDH1A1 P00352 6/20 0.46
CYP2D6 P10635 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 7/20 0.44
KMT2A Q03164 7/20 0.44
GAA P10253 3/20 0.44
LMNA P02545 4/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 9/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
MAPK1 P28482 2/20 0.41
CYP2C9 P11712 1/20 0.41
S1PR4 O95977 1/20 0.41
S1PR1 P21453 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147579 1.00 GLO1 (0.69) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL1939600 0.89 NPSR1 (0.58) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL13269641 0.89 NPSR1 (0.58) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11719302 0.84 GLO1 (0.60) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11719294 0.84 GLO1 (0.60) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL14341409 0.83 GLO1 (0.53) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11718849 0.83 GLO1 (0.64) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11718842 0.83 GLO1 (0.64) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL11378098 0.82 GLO1 (0.75) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL9278827 0.82 GLO1 (0.75) GLO1NPSR1ALDH1A1CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour GIVAUDAN SA (CH) 2008-12-11 US claimed
EP-1838278-A1 2-C-SUBSTITUTED PROPANE-1,3-DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR Givaudan SA (CH) 2007-10-03 EP claimed
WO-2006076821-A1 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR GIVAUDAN SA (CH) 2006-07-27 WO claimed
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-02-08 US disclosed
EP-4288022-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2023-12-13 EP disclosed
WO-2022167123-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2022-08-11 WO disclosed
EP-4039244-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2022-08-10 EP disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour GIVAUDAN SA (CH) 2008-12-11 US disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
EP-1838278-A1 2-C-SUBSTITUTED PROPANE-1,3-DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR Givaudan SA (CH) 2007-10-03 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed
WO-2006076821-A1 2 -C-SUBSTITUTED PROPANE-1, 3 -DICARBONYL COMPOUNDS AND THEIR USE IN NEUTRALISING MALODOUR GIVAUDAN SA (CH) 2006-07-27 WO disclosed
US-5298619-A Platelet activating factor, antiinflammatory agents, allergens and for immunodeficient syndromes ALTER, S.A. (ES) 1994-03-29 US disclosed
EP-0531598-A1 1,4-Dihydropyridines with paf-antagonistic activity ALTER, S.A. (ES) 1993-03-17 EP disclosed
US-4025537-A Preparation of 3-carboalkoxy or 3-alkanoyl furans KRETCHMER RICHARD ALLAN 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305066-A1 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour TYR, MAL2, ACMSD GLO1 171/4885NPSR1 4097/4885ALDH1A1 152/4885
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AOX1, TYR, OCIAD1 GLO1 36/4885NPSR1 3248/4885ALDH1A1 116/4885
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB GLO1 3290/4885NPSR1 920/4885ALDH1A1 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.